72.6 F
New York
Monday, May 17, 2021

Pfizer [NYSE: PFE] Announces Acquisition of Amplyx Pharmaceuticals

Must read

Oaktree [NASDAQ: OCSL] Announces Pricing of Underwritten Public Offering

Oaktree Specialty Lending Corporation disclosed that it has set the price of an underwritten public offering of $350.0 million aggregate principal amount of...

Black.one Introduces Cryptocurrency Exchange Venture with $10B in Funding

Black.one has disclosed Tuesday that it has launched Bullish Global. Bullish Global is a subsidiary of Black.one. It is a new blockchain-based cryptocurrency exchange...

Pfizer-BioNTech COVID-19 Vaccine Gets FA Approval for Emergency Use in Adolescents

Pfizer Inc. and BioNTech SE disclosed that its COVID-19 vaccine has got the FDA approval for its COVID-19 vaccine. After the approval,...

Soliton [NASDAQ: SOLY] to be Acquired by Allergan Aesthetics

Soliton, Inc. disclosed Monday that it has inked an agreement with Allergen Aesthetics. As per the agreement, Allergen Aesthetics will buy Soliton. Allergen...

Pfizer Inc. [NYSE: PFE] has declared the acquisition of Amplyx Pharmaceuticals on Wednesday. Amplyx has gained recognition as a private firm that has pledged to the advancement of therapies for critical illnesses that afflict people with imperiled immune systems.

Presently, the top candidate of the firm is Fosmanogepix (APX001). It is a novel examination asset under progress for the therapy of invasive fungal infections. Each year the world has reported more than 1.5 million cases of invasive fungal infection.

Furthermore, the world has experienced a mortality rate as high as 30-80% across infection types. Fosmanogepix has the ability to target fungal strains repellent to the standard of care therapy. Presently, there are only three classes of antifungal remedies.

The new cure of Amplyx is a ray of hope for both physicians and sufferers. US FDA has not provided any authorization to any novel therapeutic class of antifungal therapies in nearly two decades.

Fosmanogepix Phase II Clinical Trials

Fosmanogepix is presently in Phase II clinical study. The purpose of the study is to assess the safety and potency of both intravenous (IV) and oral formulations for the cure of sufferers with critical invasive fungal infections caused by molds, yeasts, and rare molds.

Furthermore, with this buying of Ampylyx PFE not only acquire Fosmanogepix but also got the ownership of Amplyx’s early-stage pipeline that involves potential antiviral (MAU868) and antifungal (APX2039) cures. The firm has not yet disclosed the terms of the agreement.

More articles

Latest article

Elon Musk’s SpaceX to Roll Out Dogecoin-Backed Satellite to the Moon in 2022

Elon Musk’s SpaceX has decided to recognize Dogecoin as payment to roll out its “DOGE-1 Mission to the Moon”. The mission is going to...

SBI CEO Yoshitaka Kitao Reveals Ripple to Go Public after its Legal Battle with the SEC is Over

CEO of Japanese financial services company SBI Holdings, Yoshitaka Kitao disclosed that Ripple has opted for an option to go public once its legal...

Coinbase Pro Announces it will be Listing Internet Computer’s ICP

Coinbase Pro cryptocurrency exchange has disclosed that it has decided to list ICP once it goes live. ICP is the governance token of the...

WISeKey [NASDAQ: WKEY] Gets Investment to finance its TrustNFT.IO NFT Platform

WISeKey International Holding AG disclosed Friday that it has inked a term-sheet to enter into an unsecured short-term loan and the issuance and...

Moderna [NASDAQ: MRNA] Inks Supply Agreement with Switzerland

Moderna, Inc. disclosed that it has inked a supply agreement on Thursday with the Swiss Federal Government. As per the agreement, Moderna Inc...

TeraBlock Will Have its Own BSCPad IDO Soon

TeraBlock which is a project making a platform for automated cryptocurrency portfolio management disclosed that it is preparing for an initial DEX offering (IDO)...

Why Chiasma [NASDAQ: CHMA] Stock is Skyrocketed?

Shares of Chiasma, Inc. surged 46.48% during the trading session of Wednesday. Chiasma has disclosed the financial results for the Q1 completed March...

NeoGenomics [NASDAQ: NEO] Announces Acquisition of Inivata Ltd

NeoGenomics, Inc. revealed Wednesday that it has decided to purchase Inivata Ltd. Inivata will grow into a liquid biopsy-centered division together with increasing...